Armata Pharmaceuticals, Inc.

AMEX:ARMP

Biotechnology

Healthcare
$3.17 -0.28%

-$0.02 today

Market cap
$117.90M
Beta
1.22
P/E (TTM)
-0.9
EPS (TTM)
-$7.74
52W Low $1.81High $16.34

Volume 0.09M

Average 0.07M

ARMP Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Armata Pharmaceuticals, Inc.AMEX: ARMP

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue growth accelerates

Q1 FY2026 revenue of $789K rose 60.7% year over year, ahead of the -37.1% change in trailing-twelve-month revenue. Over 3 fiscal years it compounded at -3.8% a year.

Context

  • Revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 1 analysts of $6.15M (+25.4%) for the fiscal year ending Dec 2026, a step up from the -5.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$789K— QoQ
Last fiscal yearDec 2025
$4.9M-5.2% YoY
LTMMar 2026
$2.96M-37.1% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+60.7%-81.6%-142.3 pp
1 year-5.2%+25.4%+30.6 pp
3-year CAGR-3.8%+125.6%+129.4 pp
5-year CAGR+63.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
4.9M USD
Year-over-year change
-5.2%
4-year CAGR
+2.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How ARMP compares with its peers on the latest reported figures

  • ARMP's LTM Mar 2026 revenue of $2.96M is the lowest of the 2 companies compared; the peer median is $54.77M.
  • Its year-over-year change of -37.1% is the lowest of 2, against a peer median of +22.8%.
  • Over three fiscal years its annual growth of -3.8% compares with a peer median of +7.1%.
ARMP Competitors Peer median
Revenue for ARMP and competitors
Company Period LTM YoY 3-year CAGR
SPROSpero Therapeutics, Inc.LTM Mar 2026$54.77M +22.8%+7.1%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$2.96M -37.1%-3.8%
Peer median (excluding ARMP) $54.77M+22.8%+7.1%

Competitors are the stored peer set for ARMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.47M5.51M4.53M5.17M4.9M
Cost of Revenue20.02M35.02M972K34.43M1.53M
Gross Profit(15.54M)(29.51M)3.56M(29.25M)3.37M
Gross Margin-347.4%-535.7%78.5%-565.4%68.8%
Research & Development20.02M35.02M33.77M34.43M23.72M
Selling, General & Admin8.28M7.44M10.68M13.18M12.41M
Operating Expenses8.28M7.44M44.45M13.18M34.6M
Depreciation & Amortization1.17M892K972K1.33M1.53M
EBITDA(21.92M)(36M)(65.45M)(6.85M)(155.68M)
EBITDA Margin-490.0%-653.5%-1445.1%-132.4%-3174.5%
Operating Income(23.82M)(36.95M)(40.89M)(42.44M)(31.22M)
Operating Margin-532.5%-670.8%-902.8%-820.2%-636.7%
Interest Income5K29K179K697K388K
Interest Expense64K29K2.63M10.74M16.59M
Other Income / Expenses667K29K(28.16M)23.52M(142.58M)
Income Before Tax(23.16M)(36.92M)(69.05M)(18.92M)(173.8M)
Pre-Tax Margin-517.5%-670.2%-1524.5%-365.6%-3544.0%
Income Tax Expense00000
Net Income(23.16M)(36.92M)(69.05M)(18.92M)(173.8M)
Net Margin-517.5%-670.2%-1524.5%-365.6%-3544.0%
EPS (Basic)(0.96)(1.08)(1.91)(0.52)(4.80)
EPS (Diluted)(0.96)(1.08)(1.91)(0.52)(4.80)
Weighted Avg Shares24.1M34.29M36.08M36.16M36.24M
Weighted Avg Shares (Diluted)24.1M34.29M36.08M36.16M36.24M

Armata Pharmaceuticals, Inc.

AMEX:ARMP

Intrinsic Alpha fair value

Locked

Current Price

$3.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.